Gelatin Capsule Shell Cross-Linking - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Gelatin Capsule Shell Cross-Linking
The authors develop a pratical approach to avoid unwanted interactions between pepsin and SLS in dissolution Tier II tests.


Pharmaceutical Technology
Volume 35, Issue 5, pp. 62-68

Methods

Dissolution methods. Tier I dissolution was performed using USP paddle apparatus in 900 mL of 0.01 N HCl with 1.0% SLS in each vessel at 37 C. The paddle rotation speed was 75 rpm.

Samples were obtained at predetermined time points of 10, 20, 30, 45, and 60 min. After 60 min the paddle speed was increased to 250 rpm for another 15 min before samples at the "infinity" time point were withdrawn. All samples were analyzed using a UV–Vis spectrometer at a wavelength of 266 nm.

The initial Tier II dissolution method was developed following USP <711>, using a premixed medium containing 900 mL of 0.01 N HCl, 1.0% SLS and 750,000 units/L purified pepsin in each vessel.

The final Tier II dissolution method was modified from USP <711> by using 600 mL of 0.01 N HCl solution containing 750,000 units/L of purified pepsin in each vessel at the beginning of the test. After 5 min, an additional 300 mL of 0.01N HCl solution containing 3.0% SLS was added to each vessel. This medium was preheated and kept at 37 C before transferring. Other method conditions were constant


Table I: Dissolution results for capsules stored at 40 C and 75% relative humidity (RH) for 1 and 3 months.
Capsule switching test procedure. To identify the cause of dissolution slowdown, a capsule switching test was conducted. The contents of six capsules, which had been stored at 40 C and 75% RH for three months and showed dissolution slow down, were fully transferred into six fresh shells. The fresh capsule shells were from the same batch as those used in the stability study and were stored in a closed container at ambient conditions. The six emptied (i.e., aged) capsule shells, on the other hand, were refilled with a fresh drug blend made with the same formula and manufacturing process.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here